TZ2

TZ2 | Peptide Complex

Metabolic

TZ2 is a first-in-class dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor co-agonist, developed as a once-weekly injectable peptide. It is the active compound in Eli Lilly's approved therapeutics Mounjaro® (type 2 diabetes) and Zepbound® (obesity) and has become one of the most clinically significant metabolic peptides of the past decade. In research settings, Tirzepatide is studied for its unprecedented effects on body weight reduction, glycemic control, cardiovascular risk factors, and metabolic disease reversal.

• Dual Incretin Receptor Agonism — TZ2 activates both GIP and GLP-1 receptors with optimized potency ratios, producing superior glycemic control and weight reduction compared to GLP-1 mono-agonists in head-to-head research comparisons.

• Body Weight Reduction — Phase 3 SURMOUNT trials demonstrated average weight reductions of 20–22.5% from baseline, representing the most pronounced weight loss outcomes observed in a pharmaceutical compound at the time of publication.

• Glycemic Control & Beta-Cell Research — TZ2 reduces HbA1c significantly in type 2 diabetes research models, with interest in its potential to preserve and restore pancreatic beta-cell function over time.

• Cardiovascular Risk Reduction — The SURPASS-CVOT trial demonstrated significant reductions in major adverse cardiovascular events (MACE), blood pressure, and lipid panel markers in subjects with established cardiovascular disease.

• Hepatic & NASH Research — Emerging research indicates TZ2 may significantly reduce hepatic steatosis and NASH-related fibrosis, positioning it as a compound of major interest in liver disease and metabolic-associated fatty liver disease (MAFLD) research.